.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,650,486

« Back to Dashboard

Details for Patent: 5,650,486

Title: Monomeric insulin analog formulations
Abstract:The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
Inventor(s): De Felippis; Michael R. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Filing Date:Jun 01, 1995
Application Number:08/458,150
Claims:1. A process for preparing an insulin analog-protamine crystal, which comprises:

combining an aqueous solution of human insulin wherein Pro at position B28 is substituted with Asp, and Lys at position B29 is substituted with Lys or Pro in a hexamer association state, and a protamine solution at a temperature from about 5.degree. C. to about 22.degree. C.;

said aqueous solution comprising from about 0.35 to about 0.9% zinc by weight, human insulin wherein Pro at position B28 is substituted with Asp, and Lys at position B29 is substituted with Lys or Pro, and a phenolic derivative at a pH of about 7.1 to about 7.6;

said protamine solution comprising protamine at a pH of about 7.1 to about 7.6 such that the final concentration of protamine is about 0.27 to about 0.35 mg protamine to 100 IU of insulin analog.

2. The process of claim 1, wherein the process is carried out at a temperature from about 8.degree. C. to about 22.degree. C.

3. The process of claim 2, wherein the process is carried out at a temperature from about 13.degree. C. to about 17.degree. C.

4. The process of claim 3, wherein the process is carried out in less than about 4 mg/mL sodium chloride.

5. The process of claim 4, wherein the insulin is AspB28-human insulin.

6. The process of claim 5, wherein the phenotic derivative is phenol or m-cresol.

7. The process of claim 6, wherein the phenolic derivative is phenol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc